Omnicell (OMCL) AI Stock Analysis

• Market Cap: $1.73B
• Dividend Yield: N/A
• Average Volume (3M): 673.68K
• Price to Earnings (P/E): 894.2
• Beta (1Y): 0.25
• Revenue Growth: 10.67%
• EPS Growth: N/A
• Country: US
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.40
• Shares Outstanding: 44,876,522
• 10 Day Avg. Volume: 709,278
• 30 Day Avg. Volume: 673,683
• PEG Ratio: -12.16
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 1.76
• P/FCF Ratio: 23.97
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 1.57
• Enterprise Value/Gross Profit: 3.70
• Enterprise Value/Ebitda: 20.42
• 1Y Price Target: $58.20
• Price Target Upside: 47.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 1.88
• Revenue Forecast (FY): $1.24B

• Rating: 54 Neutral
• Price Target: $40.00 ▲(1.11% Upside)
• Action: Reiterated Date: 02/06/26
• Date: Action: Reiterated 02/06/26

The score is held back most by weak technicals (oversold with negative momentum) and very stretched valuation (extremely high P/E with no dividend support). Financially, debt reduction and positive free cash flow help, but thin and volatile profitability remains a key risk. Earnings call guidance is moderately constructive, but tariff-driven margin pressure and recent EPS/cash weakness temper the outlook.

Positive Factors

Balance sheet deleveraging

Material debt reduction to roughly $192M meaningfully lowers financial leverage and interest exposure. This durable improvement enhances flexibility to fund R&D, product rollouts, or strategic investments without urgent external financing, supporting multi-year execution of growth initiatives.

Positive cash generation

Consistent operating cash flow (~$127M) and positive free cash flow (~$87M) provide internal capital to fund product development, service expansion and debt reduction. Reliable cash generation supports sustainable investment in recurring-revenue initiatives and cushions execution risk.

Recurring revenue / ARR growth

ARR expansion to $636M (+10%) and growing service revenue increase revenue visibility and customer stickiness. A larger recurring base shifts mix toward predictable cashflows, improving long-term revenue stability and creating a platform for higher-margin software monetization over coming years.

Negative Factors

Thin, volatile profitability

Very low net margins and historical earnings volatility undermine the company's ability to convert growth into durable returns. Thin profitability limits reinvestment capacity and makes long-term value creation highly dependent on sustained margin recovery and consistent cost control.

Gross margin pressure from tariffs

A ~4.2pp gross margin decline driven partly by tariffs (and an estimated ~$15M 2026 tariff impact) is a structural headwind. Persistent tariff and supply-chain costs will compress durable profitability unless offset by pricing, sourcing changes, or productivity gains.

Delayed monetization of new hardware

New product launches face multi-quarter-to-multi-year replacement cycles; no Titan XT orders in 2025 shows slow near-term monetization. Reliance on long capital cycles and financing solutions delays revenue realization and extends the timeline to earn returns on R&D investments.

Omnicell Business Overview & Revenue Model

Company Description

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

How the Company Makes Money

Omnicell generates revenue through multiple streams, primarily by selling its automated dispensing systems and software solutions to healthcare providers. The company earns a significant portion of its revenue from the sale of hardware, including automated medication dispensing units and robotic systems. In addition to hardware sales, Omnicell also offers software solutions, maintenance contracts, and services that enhance the operational capabilities of its clients, creating recurring revenue through subscription and service contracts. Furthermore, strategic partnerships with healthcare organizations and technology providers contribute to its earnings by expanding market reach and integrating its solutions into existing healthcare infrastructures. The combination of these revenue streams allows Omnicell to maintain a robust financial model, driven by ongoing demand for healthcare efficiency and safety improvements.

Omnicell Financial Statement Overview

Summary

Balance sheet strength improved meaningfully with large debt reduction and sizable equity, and cash generation remains solid with positive operating cash flow and free cash flow. However, earnings quality is the main constraint: despite the 2025 revenue rebound, profitability is very thin and has been volatile, and free cash flow declined year-over-year.

Income Statement

Revenue rebounded in 2025 (+60.3% vs. 2024), but profitability deteriorated sharply: net margin fell to ~0.2% (from ~1.1% in 2024) and operating profit was essentially flat/near-zero despite solid gross margin stability (~42–46% range over the period). Results have also been volatile (loss in 2023, strong profitability in 2021), suggesting earnings quality and cost structure are still not consistently controlled.

Balance Sheet

Leverage improved materially, with total debt down to ~$192M in 2025 from ~$383M in 2024 and ~$614M in 2023, while equity remained large (~$1.23B). Total assets are steady (~$2.0B), giving the company flexibility. The key weakness is low recent profitability, which limits returns on the equity base and reduces the balance sheet’s ability to compound value without an earnings recovery.

Cash Flow

Cash generation is a relative bright spot: 2025 operating cash flow was ~$127M and free cash flow was ~$87M, remaining solidly positive. That said, free cash flow declined ~22% in 2025 versus 2024, indicating weaker conversion year-over-year. Over the broader period, cash flow has been materially stronger than the 2022 trough, but the recent downshift and thin net income in 2025 warrant monitoring.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.18B	1.11B	1.15B	1.30B	1.13B
Gross Profit	503.44M	471.00M	499.93M	588.99M	554.65M
EBITDA	90.12M	90.09M	79.98M	96.85M	174.44M
Net Income	2.05M	12.53M	-20.37M	5.65M	77.85M
Balance Sheet
Total Assets	1.97B	2.12B	2.23B	2.21B	2.14B
Cash, Cash Equivalents and Short-Term Investments	196.52M	381.68M	467.97M	341.85M	359.72M
Total Debt	217.18M	382.55M	614.09M	616.74M	541.01M
Total Liabilities	742.91M	877.65M	1.04B	1.08B	995.81M
Stockholders Equity	1.23B	1.24B	1.19B	1.13B	1.15B
Cash Flow
Free Cash Flow	86.89M	151.26M	139.62M	17.04M	202.84M
Operating Cash Flow	127.30M	187.72M	181.09M	77.78M	231.81M
Investing Cash Flow	-60.36M	-52.79M	-55.02M	-58.67M	-412.50M
Financing Cash Flow	-218.32M	-235.58M	23.42M	-20.95M	47.36M

Omnicell Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 39.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Neutral. The current price of 39.56 is below the 20-day moving average (MA) of 42.25, below the 50-day MA of 45.35, and above the 200-day MA of 34.84, indicating a neutral trend. The MACD of -2.30 indicates Positive momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 82.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OMCL.

Omnicell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CERT	62 Neutral	$1.07B	99.26	1.03%	―	11.47%	―
GDRX	58 Neutral	$804.46M	27.59	4.90%	―	1.30%	―
TXG	55 Neutral	$2.44B	-54.63	-5.78%	―	1.92%	59.18%
OMCL	54 Neutral	$1.73B	894.21	0.17%	―	10.67%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	47 Neutral	$285.70M	-1.63	-13.63%	―	-16.65%	-71.92%
TDOC	47 Neutral	$805.73M	-3.55	-15.42%	―	-2.37%	77.85%

Omnicell Corporate Events

Omnicell Launches Advanced Titan XT Dispensing System

On December 8, 2025, Omnicell announced the launch of Omnicell Titan XT, an advanced automated dispensing system designed to enhance autonomous medication management. The Titan XT, powered by the cloud-based OmniSphere platform, aims to improve pharmacy control and nursing confidence by offering a connected medication management ecosystem. This innovation is expected to optimize medication inventory management and streamline nursing workflows, marking a significant milestone in Omnicell’s journey towards comprehensive healthcare automation.

The most recent analyst rating on (OMCL) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.